Avalyn Pharma COO reports stock option holdings

Avalyn Pharma Inc. Chief Operating Officer Melissa Rhodes filed an initial ownership report showing her existing stock option holdings in the company.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Avalyn Pharma Inc. Chief Operating Officer Melissa Rhodes filed an initial ownership report showing her existing stock option holdings in the company. She holds stock options over 111,123 shares of common stock with a $4.81 exercise price expiring on September 10, 2035, and options over 183,938 shares with a $4.62 exercise price expiring on January 25, 2034.

For the first option, 25% of the underlying shares vested and became exercisable on September 11, 2024, with the remaining 75% vesting in thirty-six substantially equal monthly installments, subject to her continued service. For the second, 25% of the shares vest on May 29, 2026, with the remaining 75% vesting in thirty-six substantially equal monthly installments on the same service-based terms.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Rhodes Melissa

Role Chief Operating Officer

Type	Security	Shares	Price	Value
holding	Stock Option (right to buy)	--	--	--
holding	Stock Option (right to buy)	--	--	--

Holdings After Transaction: Stock Option (right to buy) — 295,061 contracts (Direct)

Footnotes (2)

F1. 25% of the shares underlying this option vested and became exercisable on September 11, 2024, with the remaining 75% vesting in thirty-six (36) substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
F2. 25% of the shares underlying this option vest and become exercisable on May 29, 2026, with the remaining 75% vesting in thirty-six (36) substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Key Figures

Underlying shares (option 1): 111,123 shares Exercise price (option 1): $4.81 per share Underlying shares (option 2): 183,938 shares +3 more

6 metrics

Underlying shares (option 1) 111,123 shares Stock option over common stock, exercise price $4.81

Exercise price (option 1) $4.81 per share Stock Option (right to buy), expires September 10, 2035

Underlying shares (option 2) 183,938 shares Stock option over common stock, exercise price $4.62

Exercise price (option 2) $4.62 per share Stock Option (right to buy), expires January 25, 2034

Vesting start (option 1) 25% on September 11, 2024 Remaining 75% in 36 substantially equal monthly installments

Vesting start (option 2) 25% on May 29, 2026 Remaining 75% in 36 substantially equal monthly installments

Key Terms

Stock Option (right to buy), underlying security, exercise price, vesting, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

underlying security financial

"underlying_security_title: Common Stock"

exercise price financial

"conversion_or_exercise_price: 4.8100"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"25% of the shares underlying this option vested and became exercisable"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

substantially equal monthly installments financial

"vesting in thirty-six (36) substantially equal monthly installments thereafter"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Avalyn Pharma (AVLN) COO Melissa Rhodes report on this Form 3?

Melissa Rhodes reports existing stock option holdings in Avalyn Pharma common stock. She holds options over 111,123 shares at $4.81 and 183,938 shares at $4.62, both held directly, with specified vesting schedules and expiration dates.

How many Avalyn Pharma (AVLN) shares underlie Melissa Rhodes’ reported stock options?

The filing shows options over 111,123 underlying shares of common stock in one grant and 183,938 underlying shares in another. These options are reported as direct holdings and represent potential future share ownership if exercised under their terms.

What are the exercise prices and expirations of Melissa Rhodes’ Avalyn Pharma options?

One stock option has a $4.81 exercise price and expires on September 10, 2035. The other has a $4.62 exercise price and expires on January 25, 2034. Both relate to Avalyn Pharma common stock.

How do Melissa Rhodes’ Avalyn Pharma (AVLN) stock options vest?

For the first option, 25% vested on September 11, 2024, with the remaining 75% vesting in thirty-six substantially equal monthly installments. For the second, 25% vest on May 29, 2026, with the remaining 75% vesting similarly, conditioned on continued service.

Does this Avalyn Pharma (AVLN) Form 3 show buys or sells by Melissa Rhodes?

The Form 3 functions as an initial ownership report and lists existing stock option holdings. The summarized data show holding entries and unknown transaction codes, with no recorded buy, sell, or option exercise transactions in this disclosure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 04/29/2026 - 06:36 PM

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Rhodes Melissa

(Last)

(First)

(Middle)

105 W FIRST STREET

(Street)

BOSTON

MASSACHUSETTS

02127

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
04/29/2026

3. Issuer Name and Ticker or Trading Symbol
Avalyn Pharma Inc. [ AVLN ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Operating Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (right to buy)	⁽¹⁾	01/25/2034	Common Stock	183,938	$4.62	D
Stock Option (right to buy)	⁽²⁾	09/10/2035	Common Stock	111,123	$4.81	D

Explanation of Responses:

1. 25% of the shares underlying this option vested and became exercisable on September 11, 2024, with the remaining 75% vesting in thirty-six (36) substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

2. 25% of the shares underlying this option vest and become exercisable on May 29, 2026, with the remaining 75% vesting in thirty-six (36) substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Douglas Carlson	04/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR